We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11B
AUM Growth
+$1.48B
Cap. Flow
-$1.03B
Cap. Flow %
-9.36%
Top 10 Hldgs %
83.4%
Holding
140
New
7
Increased
14
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.6M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$44.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.8M
4
NGNE icon
Neurogene
NGNE
+$28.1M
5
EXEL icon
Exelixis
EXEL
+$25.4M

Top Sells

Rank Stock Value
1
XNPT
XENOPORT, INC.
XNPT
+$24.5M
2
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
3
NVAX icon
Novavax
NVAX
+$17.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.2M
5
INSM icon
Insmed
INSM
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 82.76%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVIV
76
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$2.72M 0.02%
21
– –
ECYT
77
DELISTED
Endocyte, Inc. Common Stock
ECYT
$2.69M 0.02%
868,983
-261,594
-23% -$815K
SYRE icon
78
Spyre Therapeutics
SYRE
$8.76B
$2.59M 0.02%
16,169
– –
RNAC icon
79
Cartesian Therapeutics
RNAC
$220M
$2.55M 0.02%
5,965
– –
OSIR
80
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$2.48M 0.02%
499,193
– –
NBRV
81
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.47M 0.02%
1,400
– –
JUNO
82
DELISTED
Juno Therapeutics, Inc.
JUNO
$2.4M 0.02%
80,000
– –
EPZM
83
DELISTED
Epizyme, Inc
EPZM
$2.29M 0.02%
232,481
– –
KPTI icon
84
Karyopharm Therapeutics
KPTI
$158M
$2.11M 0.02%
14,466
– –
IONS icon
85
Ionis Pharmaceuticals
IONS
$9.07B
$2.09M 0.02%
57,140
– –
ENTA icon
86
Enanta Pharmaceuticals
ENTA
$369M
$2M 0.02%
75,357
– –
SCYX icon
87
SCYNEXIS
SCYX
$37.1M
$1.81M 0.02%
5,845
– –
ASMB icon
88
Assembly Biosciences
ASMB
$507M
$1.8M 0.02%
20,833
– –
QURE icon
89
uniQure
QURE
$2.79B
$1.76M 0.02%
230,000
– –
MDWD icon
90
MediWound
MDWD
$186M
$1.74M 0.02%
32,286
– –
ISEE
91
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.64M 0.01%
35,649
– –
MYOK
92
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.63M 0.01%
+100,000
New +$1.81M
MCRB icon
93
Seres Therapeutics
MCRB
$45.9M
$1.54M 0.01%
6,250
– –
PTN
94
Palatin Technologies
PTN
$14.1M
$1.29M 0.01%
1,640
– –
CLLS
95
Cellectis
CLLS
$289M
$1.2M 0.01%
50,000
– –
CLCD
96
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$1.16M 0.01%
+30,310
New +$448K
FLGT icon
97
Fulgent Genetics
FLGT
$566M
$1.15M 0.01%
+125,000
New +$1.15M
IMDZ
98
DELISTED
Immune Design Corp.
IMDZ
$1.13M 0.01%
148,937
– –
AFMD
99
DELISTED
Affimed
AFMD
$1.11M 0.01%
40,000
– –
ALDX icon
100
Aldeyra Therapeutics
ALDX
$97.1M
$1.11M 0.01%
142,000
– –
2 3
4
5 6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Baker Bros. Advisors held 140 positions worth $11B, up 16% from $9.54B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors withdrew a net $1.03B in Q3 2016, closing 6 positions and reducing 16 holdings. Its most notable exit was XENOPORT, INC., an estimated $24.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 81% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in ContraFect Corporation worth $10M.

  • Baker Bros. Advisors's largest Q3 2016 buy was ContraFect Corporation: 5,057 shares worth $10M.
  • Baker Bros. Advisors added most to Amarin Corp in Q3 2016, an estimated $55.6M increase.
  • Baker Bros. Advisors's biggest Q3 2016 reduction was BioCryst Pharmaceuticals, cutting an estimated $16.2M.
  • Baker Bros. Advisors fully exited XENOPORT, INC. in Q3 2016, selling an estimated $24.5M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $11B portfolio in Q3 2016.
  • Baker Bros. Advisors opened 7 new positions and closed 6 in Q3 2016.
  • Baker Bros. Advisors's portfolio value rose 16% quarter-over-quarter to $11B.

Based on Baker Bros. Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.